288 results about "HPV infection" patented technology

This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HPV infection.

The present invention provides systems for identifying anti-viral agents. In particular, the invention encompasses reagents and strategies for identifying agents that inhibit or disrupt key protein-protein interactions that are important in the life cycle of papillomaviruses. The invention allows identification, production, and/or use of agents that reduce or inhibit the replication of HPV by inhibiting (e.g., precluding, reversing, or disrupting) the formation of the E1-E2 protein-protein complex. The invention also provides specific inhibitory agents, pharmaceutical compositions, and methods of using these inhibitors and pharmaceutical compositions for inhibiting viral replication in vitro. Methods are also described for the treatment and prevention of HPV infections and HPV-related diseases in patients.

The present invention provides a purification method of human papillomavirus late protein L1 from escherichia coli. Virus-like Particles; the virus-like Particles with elctrophoresis purity more than 98 percent can be produced in a large scale through salt free precipitation, re-dissolving, ion exchange chromatography, hydrophobic interaction chromatography and renaturation of the L1 protein in the lysate supernatant of escherichia coli. With good immunogenicity, the virus particles can induce neutralizing antibodies towards homologous HPV virus, and can be used as a vaccine for preventing the infection of HPV.

The present invention relates to compounds that are useful in the treatment of human papillomaviruses, and also to the methods for the making and use of such compounds.

The invention provides materials and methods for detection and typing of HPV infection using PNA probes. More specifically, methods are provided for detecting high-risk types of HPV infection with minimal numbers of PNA probes or using PNA probes to selectively amplify only high-risk types of HPV. Novel primer sequences are also provided.

The present invention relates to a method and kit for quantitative and qualitative determination of human papillomavirus, HPV, in a sample. More precisely, for quantitative and qualitative determination of oncogenic HPV to predict the risk of HPV infection resulting in cervical carcinoma. The method and kit enable simultaneous measurement of several oncogenic HPV types.

The present invention relates to a method for the early diagnosis of neoplastic disorders such as cancers as well as their precursor stages, particularly cancers of the respiratory tract, the urinary system, the reproductive tract, cancer associated with HPV infection or cancer of the anogenital tract, from solubilized body samples. The invention is also directed to test kits usable for this purpose as well as in-vitro diagnostic devices. The development of the kits and in-vitro diagnostic devices for the above purpose is also one aspect of the present invention.

This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HPV infection.

The present invention relates to combined vaccines against measles and human papilloma virus (HPV). In particular, the invention relates to recombinant measles virus vectors containing heterologous nucleic acid encoding single or several antigens derived from HPV, preferably, the major capside antigen L1, the minor capside antigen L2, the early gene E6 and the early gene E7 oncoproteins of HPV type 16, and optionally of types 18, 6 and 11. In a first embodiment, prophylactic vaccines are generated expressing HPV antigens, preferably L1 and/or L2 such that they induce a potent long-lasting immune response in mammals, preferably humans, to protect against HPV and MV infection. In another embodiment, therapeutic vaccines are generated expressing E6 and E7 proteins, and optionally L1 and L2, such that they induced strong immune responses will resolve persistent HPV infections at early or late stages, including HPV-induced cervical carcinoma. In a preferred embodiment, the combined vaccines are easy to produce on a large scale and can be distributed at low cost.

The present invention relates to human papillomavirus (HPV) type hybrid virus-like particles and a preparation method thereof. The virus-like particles can be used for preventions two or more HPV infections and diseases caused by HPV infections. The present invention further relates to uses of the protein and the virus-like particles in preparations of drug compositions or vaccines, wherein the drug compositions or the vaccines are provided for preventions of HPV infections and diseases caused by HPV infections, and the diseases comprise cervical cancer, condyloma acuminatum, and the like.

The invention provides a monoclonal rabbit antibody for identifying HPV16 positive cervical tissues. The antibody can be used for specifically detecting a biomarker HPV16E7 protein in tissues including cervical cancer and cervical lesions, so that HPV persistent infection related cervical cancer tissues from abnormal or noncancerous cervical epithelial tissues, cervical cancer caused by high-risk HPV infection can be accurately diagnosed, and risk early-warning can be especially performed for whether early cervical lesions cancerate or not, so that the misdiagnosed rate of cervical lesions can be effectively reduced, and injuries and resource waste caused by over treatment for patients can be improved.

Synthetic DNA molecules encoding the HPV58 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV58 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV58 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV58 VLPs. The vaccines of the present invention provide effective imnunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity and are also useful for treatment of existing HPV infections.

The invention discloses a probe with a nucleotide sequence complementary to human papilloma virus HPV DNA, a genotyping detection kit containing the probe and a gene chip preparation method thereof. The probe is selected from SEQ ID Nos: 1-21 and sequences complementary to SEQ ID Nos: 1-21. The kit includes a gene chip with at least one of the above-mentioned probes, a DNA sequence marked with biotin spots, a DNA sequence coding a part of β-globulin, and various primers selected from MY09/MY11. The gene chip of the kit is prepared through the steps of preparing DNA probes, fixing the probes, using sodium hydroxide to stop the reaction, and the like. The kit of the invention can quickly and accurately detect HPV infection and identify specific subtypes, is more suitable for Chinese people, and has great significance for early diagnosis, prevention, treatment and follow-up of cervical cancer.

Embodiments of the invention provide methods, assays, and kits for detecting HPV infection and HPV associated epithelial cell abnormalities, most notably those associated with pre-malignant and malignant epithelial cell lesions. Detection of HPV DNAs, genomes, and/or oncoproteins by nucleic acid hybridization assays and immunological assays can be used in early clinical screening for HPV infection and diagnosis for cervical cancer. The polypeptides, recombinant proteins, antibodies, nucleic acids, and various detection methods thereof are particularly useful for diagnosing carcinomas of the uterine cervix and those at risk of developing cervical cancer.

The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.

The invention provides peptides designed to be highly reactive with antibodies from patients infected with oncogenic HPV. Also disclosed is a method for their use in an immunoassay to detect HPV infection and HPV associated epithelial cell abnormalities, most notably those associated with premalignant and malignant epithelial cell lesions. The peptides and the disclosed method are particularly useful for diagnosing carcinomas of the uterine cervix, or pre-stages thereof, or those at risk of development of carcinoma. The detection can be effected on blood samples, or other bodily fluid or tissue, by ascertaining the presence of IgA or IgG antibodies against HPV 16 and/or 18.

The invention discloses an externally-used traditional Chinese medicine composition for treating cervical HPV infection and a preparation method thereof; the composition mainly comprises the following raw material herbs of lithospermum, phellodendron, curcuma rhizome, honeysuckle flowers, radix sophorae flavescentis, radix stemonae, bletilla striata, and borneol; the preparation method comprises the following steps: performing water vapor distillation extraction of curcuma rhizome, performing clathration of volatile oil and borneol by using betw-cyclodextrin; decocting the herb residues, honeysuckle flowers and bletilla striata with water, combining with the distilled fluid, filtering and concentrating the mixed fluid to obtain an extract 1; performing ethanol reflux extraction of lithospermum, phellodendron, radix sophorae flavescentis, and radix stemonae, filtering and concentrating to obtain an extract 2; combining the extract 1 with 2; combining the combined extract with the clathrate, adding pharmaceutically acceptable auxiliary materials to prepare a clinically acceptable dosage form for external use. The traditional Chinese medicine composition of the invention has definite and obvious therapeutic effect on treating cervical HPV infection, overcomes the inconvenience of original powder administration, is convenient for clinical application, and has less side effect.

The present invention provides a monoclonal antibody for identifying HPV18 positive cervical epithelial cancer cells, and applications thereof. According to the present invention, with the monoclonal antibody, the cervical cancer biomarker HPV18E7 protein in the tumor cells can be detected in a highly specific manner so as to distinguish between the cancerous cervical epithelial cells and the abnormal cervical epithelial cells or non-cancerous cervical epithelial cells and provide basis for the accurate diagnose of the cancer caused by the HPV infection, such that the treatment can be timely taken, the cancer occurrence or cancer spreading can be prevented, and the suffering of patients can be alleviated.

Synthetic DNA molecules encoding the HPV 52 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV 52 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. In alternative embodiments of the invention, the nucleotide sequence of the synthetic molecule is altered to eliminate transcription termination signals that are recognized by yeast. The synthetic molecules may be used to produce HPV 52 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV 52 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity and may also be useful for treatment of existing HPV infections.

The present invention is directed to HPV polyepitope construct and the use thereoffor the prevention and/or treatment of HPV infection.

The present invention relates to a human papillomavirus (HPV) vaccine that comprises peptides from host cell proteins and more particularly, a vaccine that is directed against cancers that are associated with HPV infections, such as cervical cancer, head and neck cancer and skin cancers. The peptides comprise fragments of host cell proteins that have been targeted for degradation by HPV proteins, such as E6 and E7 and are presented on the surface of HPV infected cells in relatively large amounts. These peptides can be recognised by CTL and elicit an immune response, and are therefore ideal tumour-specific markers. The invention also relates to novel peptide: peptide complexes such as peptide/HLA complexes and their use in a tumour-specific vaccine.